The news comes two months after a reported agreement was signed for the investment.
Biopharmaceutical company Kamada Ltd. (TASE:KMDA) has raised NIS 29 million from its founder Ralph Hahn and investment group UDT Med Holdings. The news comes two months after a reported agreement was signed for the investment.
Kamada reported that it will continue to seek additional investment funds. The company recently completed Phase III clinical trials for hereditary AAT deficiency, and Phase II trials for a treatment of cystic fibrosis.
Published by Globes [online], Israel business news - www.globes-online.com - on May 3, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009